DrugPatentWatch Database Preview
Details for Patent: 6,673,838
Which drugs does patent 6,673,838 protect, and when does it expire?
Patent 6,673,838 protects PRISTIQ and is included in one NDA.
This patent has forty-three patent family members in thirty-one countries.
This patent has forty-three patent family members in thirty-one countries.
Summary for Patent: 6,673,838
| Title: | Succinate salt of O-desmethyl-venlafaxine |
| Abstract: | A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided. |
| Inventor(s): | Hadfield; Anthony F. (Nanuet, NY), Shah; Syed M. (East Hanover, NJ), Winkley; Michael W. (Campbell Hall, NY), Sutherland; Karen W. (New City, NY), Provost; James A. (Waltham Chase, GB), Park; Aeri (West Lafayette, IN), Shipplett; Rex A. (Wolcott, IN), Russell; Brenton W. (West Lafayette, IN), Weber; Beat T. (Zofingen, CH) |
| Assignee: | Wyeth (Madison, NJ) |
| Application Number: | 10/073,743 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Dosage form; Formulation; Use; |
Drugs Protected by US Patent 6,673,838
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Pharms Inc | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-003 | Aug 20, 2014 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) | ➤ Sign Up | ||
| Wyeth Pharms Inc | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-003 | Aug 20, 2014 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION | ➤ Sign Up | ||
| Wyeth Pharms Inc | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-001 | Feb 29, 2008 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) | ➤ Sign Up | ||
| Wyeth Pharms Inc | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-001 | Feb 29, 2008 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 6,673,838
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
International Patents Family Members for US Patent 6,673,838
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 032671 | ➤ Sign Up | |||
| Argentina | 082076 | ➤ Sign Up | |||
| Austria | 369330 | ➤ Sign Up | |||
| Australia | 2002250058 | ➤ Sign Up | |||
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
